| Literature DB >> 26339402 |
Kunpeng Liu1, Yuan Ren1, Lijuan Pang1, Yan Qi1, Wei Jia1, Lin Tao1, Zhengyan Hu1, Jin Zhao1, Haijun Zhang2, Li Li2, Haifeng Yue3, Juan Han3, Weihua Liang4, Jianming Hu1, Hong Zou1, Xianglin Yuan3, Feng Li1.
Abstract
Papillary renal cell carcinoma (PRCC) represents the second most common histological subtype of RCC, and comprises 2 subtypes. Prognosis for type 1 PRCC is relatively good, whereas type 2 PRCC is associated with poor clinical outcomes. The aim of the present study was to evaluate the clinicopathological and mutations characteristics of PRCC. Hence, we reported on 13 cases of PRCC analyzed using whole-exome sequencing. Histologically, type 2 PRCC showed a higher nuclear grade and lymphovascular invasion rate versus type 1 PRCC (P < 0.05). Immunostaining revealed type 1 PRCC had higher CK7 and lower Top IIα expression rates (P < 0.05). Whole-exome sequencing data analysis revealed that the mutational statuses of 373 genes (287 missense, 69 silent, 6 nonsense, and 11 synonymous mutations) differed significantly between PRCC and normal renal tissues (P < 0.05). Functional enrichment analysis was used to classify the 287 missense-mutated genes into 11 biological process clusters (comprised of 61 biological processes) and 5 pathways, involved in cell adhesion, microtubule-based movement, the cell cycle, polysaccharide biosynthesis, muscle cell development and differentiation, cell death, and negative regulation. Associated pathways included the ATP-binding cassette transporter, extracellular matrix-receptor interaction, lysosome, complement and coagulation cascades, and glyoxylate and dicarboxylate metabolism pathways. The missense mutation status of 19 genes differed significantly between the groups (P < 0.05), and alterations in the EEF1D, RFNG, GPR142, and RAB37 genes were located in different chromosomal regions in type 1 and 2 PRCC. These mutations may contribute to future studies on pathogenic mechanisms and targeted therapy of PRCC.Entities:
Keywords: Papillary renal cell carcinoma; gene mutation; whole-exome sequencing
Mesh:
Substances:
Year: 2015 PMID: 26339402 PMCID: PMC4555730
Source DB: PubMed Journal: Int J Clin Exp Pathol ISSN: 1936-2625